Literature DB >> 2373087

Disk diffusion susceptibility testing of Haemophilus influenzae using haemophilus test medium.

G V Doern1, J H Jorgensen, C Thornsberry, H Snapper.   

Abstract

A three-center collaborative study was performed with the aim of determining the reproducibility of disk diffusion and broth microdilution susceptibility tests of Haemophilus influenzae with 19 different antimicrobial agents using a newly described medium, Haemophilus Test Medium. The results of both methods were found to be highly reproducible. Using Haemophilus Test Medium, inhibitory zone diameters and MICs were then determined for 150 test strains of Haemophilus influenzae, selected with an emphasis on known mechanisms of resistance. Regression analysis of zone diameter-MIC comparisons was used to define zone diameter interpretive criteria and MIC correlates for Haemophilus Test Medium disk diffusion tests performed with Haemophilus spp. for the following antimicrobial agents: ampicillin, amoxicillin/clavulanate, ampicillin/sulbactam, cefaclor, cefuroxime, cefamandole, ceftriaxone, cefotaxime, ceftizoxime, ceftazidime, cefixime, trimethoprim/sulfamethoxazole, rifampin, chloramphenicol, tetracycline, imipenem, aztreonam and ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2373087     DOI: 10.1007/bf01973739

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  8 in total

1.  Resistance of clinical isolates of Haemophilus influenzae in United Kingdom 1986.

Authors:  M Powell; C Koutsia-Carouzou; D Voutsinas; A Seymour; J D Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1987-07-18

Review 2.  Haemophilus influenzae: antibiotic susceptibility.

Authors:  C A Needham
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

3.  Disk diffusion interpretive criteria for extended-spectrum cephalosporins with Haemophilus influenzae.

Authors:  J H Jorgensen; L A Maher; J S Redding
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

4.  Susceptibility of multiply resistant Haemophilus influenzae to newer antimicrobial agents.

Authors:  J H Jorgensen; G V Doern; C Thornsberry; D A Preston; J S Redding; L A Maher; T Tubert
Journal:  Diagn Microbiol Infect Dis       Date:  1988-01       Impact factor: 2.803

5.  Susceptibility studies of multiply resistant Haemophilus influenzae isolated from pediatric patients and contacts.

Authors:  J Campos; S Garcia-Tornel; I Sanfeliu
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

6.  Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae.

Authors:  J H Jorgensen; J S Redding; L A Maher; A W Howell
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

7.  Prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae: a collaborative study.

Authors:  G V Doern; J H Jorgensen; C Thornsberry; D A Preston
Journal:  Diagn Microbiol Infect Dis       Date:  1986-02       Impact factor: 2.803

8.  National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae.

Authors:  G V Doern; J H Jorgensen; C Thornsberry; D A Preston; T Tubert; J S Redding; L A Maher
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

  8 in total
  17 in total

Review 1.  In vitro susceptibility testing of Haemophilus influenzae: review of new National Committee for Clinical Laboratory Standards recommendations.

Authors:  G V Doern
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

2.  Biographical Feature: Clyde Thornsberry, Ph.D.

Authors:  Erik Munson
Journal:  J Clin Microbiol       Date:  2015-12-09       Impact factor: 5.948

3.  False resistance results using 5 micrograms cefixime disks to test Haemophilus influenzae.

Authors:  R N Jones; M E Erwin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-07       Impact factor: 3.267

4.  Performance of Haemophilus Test Media prepared with 12 different lots of Mueller-Hinton agar from four manufacturers.

Authors:  A L Barry; R R Packer
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

5.  Interpretive criteria for susceptibilities of Haemophilus influenzae to ampicillin, amoxicillin, and amoxicillin-clavulanic acid.

Authors:  P C Fuchs; A L Barry
Journal:  J Clin Microbiol       Date:  1994-11       Impact factor: 5.948

6.  Comparison of agar dilution, broth dilution, and disk diffusion testing of ampicillin against Haemophilus species by using in-house and commercially prepared media.

Authors:  P C Kohner; J E Rosenblatt; F R Cockerill
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

7.  Reevaluation of interpretive criteria for Haemophilus influenzae by using meropenem (10-microgram), imipenem (10-microgram), and ampicillin (2- and 10-microgram) disks.

Authors:  L Zerva; D J Biedenbach; R N Jones
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

8.  In vitro activity of loracarbef (LY163892), a new oral carbacephem antimicrobial agent, against respiratory isolates of Haemophilus influenzae and Moraxella catarrhalis.

Authors:  G V Doern; R Vautour; D Parker; T Tubert; B Torres
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

9.  Broth microdilution testing of Haemophilus influenzae with haemophilus test medium versus lysed horse blood broth. Canadian Haemophilus Study Group.

Authors:  S R Scriver; D E Low; A E Simor; B Toye; A McGeer; R Jaeger
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

10.  Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.

Authors:  Silvia García-Cobos; José Campos; Federico Román; Cristina Carrera; María Pérez-Vázquez; Belén Aracil; Jesús Oteo
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.